Charles Smith
Family Medicine · le Claire, IANPI 1861498669
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.6% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 125 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$396
- AbbVie$346
- AstraZeneca$333
- Boehringer Ingelheim$201
- Pfizer$166
- GSK$140
- plus $671 from 14 others
What the payments were for
- Food & beverage$2,15496%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $396 |
| AbbVie(2 entities) | 18 | $346 |
| AstraZeneca | 21 | $333 |
| Boehringer Ingelheim | 14 | $201 |
| Pfizer | 9 | $166 |
| GSK | 10 | $140 |
| Astellas Pharma US Inc | 3 | $131 |
| Amgen | 9 | $125 |
| Johnson & Johnson | 3 | $62 |
| Merck | 4 | $56 |
| Exact Sciences | 3 | $53 |
| Esperion Therapeutics, Inc. | 3 | $53 |
| Amarin Pharma, Inc. | 3 | $50 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Novartis | 2 | $26 |
| IBSA Pharma Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,254 in reported general payments places this provider in the 90th percentile of 1,357 family medicine providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nifedipine ErNifedipine | 12 | $225 |
| Famotidine | 12 | $103 |
| Donepezil Hcl | 13 | $76 |
Paid to pharmacies, not to this prescriber.
Other family medicine in le Claire
- Kirk PetersonHuxley$576K
- Nicholas GoetschWaterloo$525K
- Stephen HarrisonClinton$249K
- Thomas RossDes Moines$170K
- Yogesh ShahDes Moines$159K
- Leslie George PaulsenMuscatine$136K
- Dylan LoweDes Moines$105K
- Michael AbouassalyWest Burlington$88K
- Kevin DeregnierWinterset$68K
- Laura MoellerAmes$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.